Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Bibliographic Details
Main Authors:	Andrew Kent, Eduardo Davila, Jitao Guo
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-08-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/9/8/1.1.full

Similar Items

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
by: Anne W J Martens, et al.
Published: (2020-06-01)

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms
by: Paola Circosta, et al.
Published: (2018-04-01)

CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice
by: Perry Tsai, et al.
Published: (2016-01-01)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
by: Patrick J. Engelberts, et al.
Published: (2020-02-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Pt/(CuIn)xCd2(1-x)S2 Photocatalysts for Water-Splitting Reaction to Produce Hydrogen
by: Yen-Cheng Huang, et al.
Published: (2011)

Pt/(CuIn)xCd2(1-x)S2 Photocatalysts for Water-Splitting Reaction to Produce Hydrogen
by: Yen-Cheng Huang, et al.
Published: (2011)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019-03-01)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
by: Fatih M. Uckun, et al.
Published: (2021-08-01)

Preclinical development of a bispecific HIV x CD3 DART molecule that redirects T cells to kill HIV envelope (env)-expressing cells
by: J.L. Nordstrom, et al.
Published: (2017-12-01)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
by: Carmen D. Herling, et al.
Published: (2018-02-01)

Développement et caractérisation d'anticorps bispécifiques anti-ace xCD16 pour l'immunothérapie des cancers
by: Rozan, Caroline
Published: (2012)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
by: Silvia Martini, et al.
Published: (2020-10-01)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
by: Huber H, et al.
Published: (2017-02-01)

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
by: Damjan Avsec, et al.
Published: (2021-09-01)

Pt/(AgIn)xCd2(1-x)S2 Photocatalysts Prepared by Hydrothermal Method for Water-Splitting Reaction to Produce Hydrogen under Visible Light
by: Chen-xin Yu, et al.
Published: (2011)

Transmembrane signalling by the CD2 and CD4 molecules of T lymphocytes
by: Beyers, Albertus Daniel
Published: (1990)

Elimination of HIV-1/SHIV infected cells by combinations of bispecific HIV x CD3 DART® molecules
by: M. Tuyishime, et al.
Published: (2019-12-01)

The cost-effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab
by: Alla V Rudakova, et al.
Published: (2019-06-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Ferrarini, I., et al.
Published: (2022)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
by: Guillaume Richard-Carpentier, et al.
Published: (2019-10-01)

Targeting CD20 in chronic lymphocytic leukemia
by: Nahas MR, et al.
Published: (2015-03-01)

Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01)

Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease “sanctuary” during venetoclax treatment?
by: Maria Dimou, et al.
Published: (2021-04-01)

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules
by: Marina Tuyishime, et al.
Published: (2021-08-01)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
by: Kaiqi Liu, et al.
Published: (2021-09-01)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
by: Ravendra Garg, et al.
Published: (2021-02-01)

The role of CD44 in the pathophysiology of chronic lymphocytic leukemia
by: Julia Christine Gutjahr, et al.
Published: (2015-04-01)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
by: Paul J. Hampel, et al.
Published: (2021-03-01)

Impact of CD39 expression on CD4+ T lymphocytes and 6q deletion on outcome of patients with chronic lymphocytic leukemia
by: Eman Mosaad Zaki, et al.
Published: (2019-03-01)

ANTI-APOPTOTIC EFFECT OF CD95 RECEPTOR IN NA VE CD8+ T-LYMPHOCYTES IN CHILDREN WITH ACUTE INFECTIOUS MONONUCLEOSIS
by: E. N. Filatova, et al.
Published: (2016-09-01)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
by: Giovanni D’Arena, et al.
Published: (2020-11-01)

Regulation of CD38 by IRF4 in chronic lymphocytic leukemia
by: Marr, Helen Judith
Published: (2016)

Treatment of SHIV-infected, ART-suppressed rhesus macaques with bispecific HIVxCD3 DART® molecules
by: Daniel M. Gorman, et al.
Published: (2019-12-01)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
by: Alexia Vereertbrugghen, et al.
Published: (2021-07-01)

Signal transduction by the CD2 molecule of T lymphocytes and NK cells
by: Spruyt, Louise Landskroon
Published: (1992)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
by: Valerio Guarente, et al.
Published: (2021-09-01)

Evaluation of CD38 expression in Sudanese patients with chronic lymphocytic leukemia
by: Enaam Abdelrhman Abdelgader, et al.
Published: (2018-11-01)

Immunohistochemical analysis of CD34 to evaluate angiogenesis in chronic lymphocytic leukemia
by: Shaymaa M. Abdelateef, et al.
Published: (2013-07-01)

CD200: A Novel Therapeutic Target for Chronic Lymphocytic Leukemia
by: Wong, Karrie
Published: (2012)